Technology
Pipeline
About Us
About Us
Leadership
Scientific Advisory Board
News
Contact Us
Contact Us
Career
News
About Us
Leadership
Scientific Advisory Board
News
SCAI Therapeutics, ‘SCAI-001, IMD CsA1’ Domestic phase 2 “IND approval” for dry eye syndrome
Daewoong Pharmaceutical and SCAI Therapeutics begin joint development of transdermal absorption formulation treatment.
Daewoo Pharm and SCAI Therapeutics, joint research contract for eye drop formulation for macular degeneration treatment.
‘New Drug Hidden Champion’ SCAI Therapeutics attracted investment of 31.4 billion won.
1
All
Title
Content
Author
Search
Powered by KBoard
Menu